Cited by 486Pancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsPancreatitis Pathology and Treatment

A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts

Open access
Springer, Simeon, Wang, Yuxuan, Dal Molin, Marco, Masica, David L., Jiao, Yuchen, Kinde, Isaac, Blackford, Amanda, Raman, Siva P. +59 more·2015·Gastroenterology

Abstract

Background & aims The management of pancreatic cysts poses challenges to both patients and their physicians. We investigated whether a combination of molecular markers and clinical information could improve the classification of pancreatic cysts and management of patients.Methods We performed a multi-center, retrospective study of 130 patients with resected pancreatic cystic neoplasms (12 serous cystadenomas, 10 solid pseudopapillary neoplasms, 12 mucinous cystic neoplasms, and 96 intraductal papillary mucinous neoplasms). Cyst fluid was analyzed to identify subtle mutations in genes known to be mutated in pancreatic cysts (BRAF, CDKN2A, CTNNB1, GNAS, KRAS, NRAS, PIK3CA, RNF43, SMAD4, TP53, and VHL); to identify loss of heterozygozity at CDKN2A, RNF43, SMAD4, TP53, and VHL tumor suppressor loci; and to identify aneuploidy. The analyses were performed using specialized technologies for implementing and interpreting massively parallel sequencing data acquisition. An algorithm was used to select markers that could classify cyst type and grade. The accuracy of the molecular markers was compared with that of clinical markers and a combination of molecular and clinical markers.Results We identified molecular markers and clinical features that classified cyst type with 90%-100% sensitivity and 92%-98% specificity. The molecular marker panel correctly identified 67 of the 74 patients who did not require surgery and could, therefore, reduce the number of unnecessary operations by 91%.Conclusions We identified a panel of molecular markers and clinical features that show promise for the accurate classification of cystic neoplasms of the pancreas and identification of cysts that require surgery.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2015.07.041

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In mucinous pancreatic cysts, cyst fluid has been demonstrated to be an attractive substrate for demonstrating aberrant somatic mutations, microRNAs or proteins, which are correlated with either the presence of mucinous epithelium per se or the progression to high-grade dysplasia and cancer.

    “In the context of mucinous pancreatic cysts, cyst fluid has been demonstrated to be an attractive substrate for demonstrating aberrant somatic mutations, microRNAs or proteins, which are then correlated with either the presence of mucinous epithelium per se or the progression to high-grade dysplasia and cancer.60,61”

    From Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review (2021) · cites this paper as [61]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured
  • The use of high-risk groups as controls and combining molecular markers with clinical features is an important consideration when identifying biomarkers capable of selecting populations at highest risk of pancreatic ductal adenocarcinoma for screening.

    “Moreover, the use of high-risk groups as controls and combining molecular markers with clinical features is an important consideration when identifying biomarkers capable of selecting populations at highest risk of development of pancreatic ductal adenocarcinoma for screening.75”

    From Early detection of pancreatic cancer (2020) · cites this paper as [75]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 25 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. [14]Masica DL Dal Molin M Blackford A Systematic analysis of pancreatic cyst classification using clinical features from a large retrospective cohort Clin Gastroenterol Hepatol 2015 Submitted for review

Cited by

Sorted by citations

Authors
Springer, S., Wang, Y., Dal Molin, M., Masica, D. L., Jiao, Y., Kinde, I., Blackford, A., Raman, S. P., Wolfgang, C. L., Tomita, T., Niknafs, N., Douville, C., Ptak, J., Dobbyn, L., Allen, P. J., Klimstra, D. S., Schattner, M. A., Schmidt, C. M., Yip-Schneider, M., Cummings, O. W., Brand, R. E., Zeh, H. J., Singhi, A. D., Scarpa, A., Salvia, R., Malleo, G., Zamboni, G., Falconi, M., Jang, J.-Y., Kim, S.-W., Kwon, W., Hong, S.-M., Song, K.-B., Kim, S. C., Swan, N., Murphy, J., Geoghegan, J., Brugge, W., Fernandez-Del Castillo, C., Mino-Kenudson, M., Schulick, R., Edil, B. H., Adsay, V., Paulino, J., van Hooft, J., Yachida, S., Nara, S., Hiraoka, N., Yamao, K., Hijioka, S., van der Merwe, S., Goggins, M., Canto, M. I., Ahuja, N., Hirose, K., Makary, M., Weiss, M. J., Cameron, J., Pittman, M., Eshleman, J. R., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Karchin, R., Hruban, R. H., Vogelstein, B., & Lennon, A. M.
Affiliations
  • Howard Hughes Medical Institute (US)
  • Johns Hopkins University (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Indiana University Bloomington (US)
  • University of Pittsburgh (US)
  • University of Verona (IT)
  • IRCCS Ospedale San Raffaele (IT)
  • Seoul National University (KR)
  • Asan Medical Center (KR)
  • St. Vincent's University Hospital (IE)
  • Massachusetts General Hospital (US)
  • University of Colorado Boulder (US)
  • Emory University (US)
  • Hospital Curry Cabral (PT)
  • National Cancer Centre Japan (JP)
  • Aichi Cancer Center (JP)
Corresponding author
Lennon, Anne Marie
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2015-11
Volume
149
Issue
6
Pages
1501-1510
ISSN
0016-5085 (ISSN-L)
OpenAlex
W1945428417
Cited by
477
References
25
Citations by year
2026: 31 · 2025: 33 · 2024: 31 · 2023: 35 · 2022: 35 · 2021: 49 · 2020: 47 · 2019: 55 · 2018: 55 · 2017: 64 · 2016: 40 · 2015: 2
FWCI
23.44
Type
journal article
Language
en
Open access
Locations
  • Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion, cc-by-nc-nd)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Lirias (KU Leuven) (submittedVersion)
Funders
  • Lustgarten Foundation
  • Virginia and D.K. Ludwig Fund for Cancer Research
  • National Cancer Institute (P50CA-62924, R37CA043460, P50CA062924, P30CA008748, P30CA006973)
  • National Institute of General Medical Sciences (T32GM007309, T32GM007057, T32GM007814)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Keywords
pancreatic cysts, pancreatic cystic neoplasms, molecular markers, cyst classification, intraductal papillary mucinous neoplasm, serous cystadenoma, solid pseudopapillary neoplasm, mucinous cystic neoplasm, cyst fluid analysis, loss of heterozygosity, aneuploidy, tumor suppressor, BRAF, CDKN2A, CTNNB1, TP53, VHL, RNF43, SMAD4, unnecessary surgery, clinical decision-making
MeSH terms
Adult, Algorithms, Female, Genetic Testing, Humans, Male, Middle Aged, Mutation, Pancreas, Pancreatic Cyst, Phenotype, Predictive Value of Tests, Prognosis, Retrospective Studies, Biomarkers, Tumor, Genetic Predisposition to Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review